doi: 10.1001/jama.2022.18445.
Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer
- PMID: 36318150
- DOI: 10.1001/jama.2022.18445
Item in Clipboard
Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer
JAMA.
.
No abstract available
Similar articles
-
Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7. Am J Manag Care. 2012. PMID: 22693986 No abstract available.
-
[Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer].Bull Cancer. 2021 Jun;108(6):562-563. doi: 10.1016/j.bulcan.2021.04.003. Epub 2021 May 20. Bull Cancer. 2021. PMID: 34023064 French. No abstract available.
-
More than just an oncogene translocation and a kinase inhibitor: Kevin's story.J Clin Oncol. 2012 Jan 1;30(1):110-2. doi: 10.1200/JCO.2011.39.4486. Epub 2011 Nov 7. J Clin Oncol. 2012. PMID: 22067391 No abstract available.
-
Crizotinib (xalkori) for non-small cell lung cancer.Med Lett Drugs Ther. 2012 Feb 6;54(1383):11-2. Med Lett Drugs Ther. 2012. PMID: 22354221 Review. No abstract available.
-
Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.Expert Rev Anticancer Ther. 2012 Feb;12(2):151-62. doi: 10.1586/era.11.186. Expert Rev Anticancer Ther. 2012. PMID: 22316363 Review.
Cited by
-
Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer.Onco Targets Ther. 2023 Nov 29;16:1015-1020. doi: 10.2147/OTT.S440610. eCollection 2023. Onco Targets Ther. 2023. PMID: 38050583 Free PMC article.
-
Targeted therapy of RET fusion-positive non-small cell lung cancer.Front Oncol. 2022 Dec 13;12:1033484. doi: 10.3389/fonc.2022.1033484. eCollection 2022. Front Oncol. 2022. PMID: 36582799 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
